LEXINGTON, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President and Chief Executive Officer, will present at the Jefferies 2015 Healthcare Conference, June 3, 2015, at 2:00 p.m. Eastern Time in New York City.
A corresponding webcast of the presentation can be accessed by visiting:
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-305, an oral HSP90 inhibitor. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis expects to exercise options to exclusively license oral small molecule antagonists of PD-L1 and IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
For more information, visit Curis' website at www.curis.com.
CONTACT: For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 email@example.com Media Contact David Schull Russo Partners (212) 845-4271 firstname.lastname@example.org